• Journal of Dairy Science and Biotechnology
• /
• v.34 no.3
• /
• pp.181-186
• /
• 2016

Kaempferia parviflora (Krachaidam, Zingiberaceae) is used as a traditional Thai medicine for treating various ailments, including allergy, fatigue, sexual dysfunction, and ulcer. Moreover, it is also used to promote longevity and as a nerve tonic. The aim of this study was to develop functional yoghurt containing Kaempferia parviflora and to examine the physicochemical characteristics of yoghurt supplemented with different concentration of K. parviflora. To this end, we examined the pH and sensory evaluation of yoghurt containing K. parviflora. The pH of this yoghurt decreased whereas the TA increased with incubation time (up to 5 h) without altering the amounts of K. parviflora added. In the sensory evaluation, the taste, flavor, color, and overall acceptability decreased in proportion to the amount of K. parviflora added. Among the experimental group, high scores were achieved by yoghurt containing 1% K. parviflora compared with that by the control group. We conclude there is an urgent need for additional research on the production of this multi-functional yogurt (with properties including anti-obesity and anti-inflammatory), using an optimum concentration of K. Parviflora.

• Clinics in Shoulder and Elbow
• /
• v.1 no.1
• /
• pp.100-108
• /
• 1998

Surgical treatment of cubital tunnel syndrome has been reported according to a wide variety of techniques since the end of the last century. Theses range from simple decompression to various forms of nerve transposition and medial epicondylectomy. However, we could find only few reports which compare the results between different types of operations. The treatment results of medial epicondylectomy and anterior subcutaneous transposition, were analysed retrospectively. From March 1984 to January 1996, a total of 110 patients had operations for cubital tunnel syndrome. Seventy four of them were followed-up for more than one year, and only they were included in this study. Anterior subcutaneous transposition was performed in 26 patients; and medial epicondylectomy in 48 patients. There were 52 males and 22 females, with an average age of 34 years (range, 13 to 75). The average follow-up period was 40 months (range, 12 to 132). Grading system by Gabel and Amadio were used for evaluation of the patients; pain, sensory and motor dysfunction were checked preoperatively and at last follow-up. In 26 patients of anterior subcutaneous transposition, 7 (27%) were graded as excellent, 11 (42%) good, 3 (12%) fair and 5 (19%) poor. In 48 patients of medial epicondylectomy, 16 (34%) were excellent, 27 (56%) good, 3 (6%) fair and 2 (4%) poor. Sixty nine percent were excellent or good in anterior subcutaneous transposition group, while ninty percent in medial epicondylectomy group. This difference was significant statistically (p<0.01 )., From our experiences, we suggest medial epicondylectomy for the treatment of cubital tunnel syndrome, rather than anterior subcutaneous transposition.

• Journal of Veterinary Clinics
• /
• v.30 no.2
• /
• pp.107-110
• /
• 2013

A 6-year-old, castrated male Shih-tzu dog was presented due to left side facial paralysis with head tilt. Neurological examination revealed absence of facial sensation, menance response, and palpebral reflex on the left side. On magnetic resonance imaging (MRI), intracranial intra-arachnoid cyst (IIAC) was noted. The dog was poor response to steroid and dieuretic therapy. Based on characteristic historical and clinical findings, and excluding of other causes of acute facial nerve dysfunction, the dog was tentatively diagnosed as idiopathic facial paralysis. The clinical signs were improved gradually after acupuncture therapy with bee venom. Eight weeks after initial acupuncture with bee venom, the patient recovered sensory and neurological facial signs. This case report demonstrates that bee venom acupuncture for an idiopathic facial paralysis could be useful in a dog.

• Korean Journal of Clinical Pharmacy
• /
• v.22 no.4
• /
• pp.356-366
• /
• 2012

Background: Chemotherapy-induced peripheral neuropathy (CIPN) involving sensory and motor nerve damage or dysfunction is a common and serious clinical problem that affects many patients receiving cancer treatment. This condition may pose challenges for the clinician to diagnose and manage, particularly in patients with coexisting conditions or disorders that involve the peripheral nervous system. Many chemotherapeutic agents used today are associated with the development of serious and dose-limiting CIPN that can adversely affect the administration of planned therapy and can impair quality of life by interference with the patients' activities of daily living. The most important clinical objective in the evaluation of patients with CIPN is to determine their level of functional impairment involving activities of daily living. These findings are used to make medical decisions to continue, modify, delay, or stop treatment. The most commonly reported drugs to cause CIPN include taxanes, platinum agents, vinca alkaloids, thalidomide, and bortezomib. We aimed to determine PN incidence during cisplatin, carboplatin and oxaliplatin administration. Methods: We collected data from 125 patients who received at least one cycle of cisplatin, carboplatin or oxaliplatin. They completed a self-reported questionnaire and items related to their disease and peripheral neuropathy. The investigators filled in part of items about disease and treatment. Patient Neurotoxicity Qeustionnaire developed by Bionumerik company were applied for PN assessment. Results: The incidences of sensory neurotoxicities of cisplatin, carboplatin and oxaliplatin were respectively 23%, 56% and 50%. The incidences of motor neurotoxicities of cisplatin, carboplatin and oxaliplatin were respectively 18%, 42% and 19%. The incidences of severe neurotoxicities of cisplatin, carboplatin and oxaliplatin were respectively 13%, 28% and 14%. The incidences of PN were associated with cumulative dose but not age, gender and concurrent illness. 19.2% of the patients (24/125) were prescribed with gabapentin, nortriptyline or gabapentin plus nortriptyline to reduce these peripheral symptoms and 75% of the patients answered the drug were effective. Conclusion: Incidence of PN after cisplatin or oxaliplatin administration is cumulative dose-related. Physician-based assessments under-reported the incidence and severity of CIPN. To overcome this limitation, diagnostic tools specifically designed to assess peripheral neuropathy severity associated with chemotherapy must be developed.